Wall Street analysts expect Teva Pharmaceutical Industries Ltd. (TEVA) to post quarterly earnings of $0.68 per share in its upcoming report, which indicates a year-over-year decline of 1.5%. Revenues are expected to be $4.35 billion, up 0.4% from the year-ago quarter.Over the last 30 days, there has been an upward revision of 0.4% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the c ...

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaignTD is a chronic movement disorder impacting one in four people who take certain prescription mental health medications. While TD can impact your daily life, it can be treated without interrupting your mental health treatment1-4Younger individuals, men, and racial and ethnic minority groups have lower rates of formal diagnoses despite the high impact the movements often have on all aspects of ...

The Tel Aviv Stock Exchange rose today. The Tel Aviv 35 Index rose 0.45% to 3,288.20 points, the Tel Aviv 125 Index rose 0.74% to 3,363.38 points; and the BlueTech Global Index rose 1.43% to 600.56 points. The All Bond corporate bond index rose 0.07% to 418.89 points. Turnover totalled NIS 1.38 billion in equities and NIS 2.44 billion in bonds. On the foreign exchange market, the representative shekel-dollar rate was set 0.43% lower on Friday, at NIS 3.243/$, and the representative shekel-euro rate was se ...

TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in November as follows: UBS Global Healthcare ConferenceMonday, November 10, 2025, at 8:45 A.M. Eastern Time (ET) Jefferies London Healthcare ConferenceTuesday, November 18, 2025, at 11:00 A.M. Greenwich Mean Time (6:00 A.M. ET) To access a live webcast of the presentation, visit Teva’s ...

（文章来源：央视新闻客户端） 当地时间10月31日，美国食品药品监督管理局（FDA）表示，多家制药企业召回超过58万瓶被致癌物污 染的降压药盐酸哌唑嗪（prazosin hydrochloride）。FDA称，新泽西州的梯瓦制药美国公司及美源健康 服务公司已于本月初启动自愿全国召回。该药用于扩张血管、降低血压，也常被用于治疗创伤后应激障 碍（PTSD）引发的噩梦与睡眠问题。FDA在公告中指出，部分批次药物可能含有亚硝胺（N- nitrosamine）类杂质，这是一种在药品生产或储存过程中形成的潜在致癌化合物。监管机构已将此次召 回列为"二级风险事件"。 ...

召回事件概述 - 梯瓦制药美国公司召回超过580,844瓶降压药哌唑嗪盐酸盐 [1][3] - 召回原因为药品中检测出超标的可能致癌化学杂质"N-亚硝基哌唑嗪杂质C" [5] - 该杂质浓度已超过美国食品药品监督管理局设定的安全限值 [5] 召回产品详情 - 受影响药品包括1毫克、2毫克和5毫克不同剂量的版本 [5] - 召回产品为每瓶100至1000粒胶囊的包装 [5] - 该药物为用于降低高血压的α受体阻滞剂 [1] 监管机构行动 - 美国食品药品监督管理局将此次召回归类为第二级（Class II）召回 [6] - 第二级召回意味着使用该药物可能导致暂时性或医学上可逆的不良健康后果 [6] - 截至报道时，制药公司尚未就消费者应如何处理被召回产品提供指示 [6]

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best affordable stocks to buy under $20. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), announced on October 20 that it entered into a license agreement with Prestige Biopharma for “the commercialization of Tuznue (trastuzumab), a biosimilar to Herceptin” across a majority of European markets. Teva Pharmaceutical Industries Limited (TEVA): Among Small-Cap Healthcare Stocks Hedge F ...

We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries Limited's share was trading at $20.21 as of October 8th. TEVA’s trailing and forward P/E were 872.00 and 7.06 respectively according to Yahoo Finance. Eli Lilly and Company (LLY) Diabetes Medication Successful in Children and Adolescents Teva Pharmaceutical Industries (TEVA) is emerging as a compe ...

评级升级与核心观点 - 梯瓦制药的Zacks评级被上调至第2级（买入）[1] - 评级上调由影响股价的最强大力量之一——盈利预期的上升趋势所触发 [1] - 此次评级上调本质上是对公司盈利前景的积极评价，可能对其股价产生有利影响 [3] Zacks评级系统方法论 - Zacks评级完全依赖于公司盈利状况的变化，通过Zacks共识预期来追踪卖方分析师对当前及下一财年的每股收益预测 [1] - 该系统利用与盈利预测相关的四个因素，将股票分为五个等级，从第1级（强力买入）到第5级（强力卖出） [7] - 自1988年以来，Zacks第1级股票的平均年回报率达到+25% [7] 盈利预测修正的重要性 - 公司未来盈利潜力的变化（反映在盈利预测修正中）已被证明与股票短期价格走势高度相关 [4] - 机构投资者使用盈利及盈利预测来计算公司股票的公平价值，其大规模交易会导致股价变动 [4] - 对梯瓦制药而言，盈利预测上升意味着公司基本业务的改善，投资者对此改善趋势的认可应会推高股价 [5] 梯瓦制药盈利预测具体数据 - 市场预计公司在截至2025年12月的财年每股收益为2.55美元，与去年同期相比没有变化 [8] - 在过去三个月中，Zacks对该公司的共识预期已上调1.7% [8] Zacks评级系统的筛选机制 - Zacks评级系统对其覆盖的4000多只股票在任何时间点均维持“买入”和“卖出”评级的同等比例 [9] - 无论市场状况如何，只有排名前5%的股票获得“强力买入”评级，接下来的15%获得“买入”评级 [9] - 梯瓦制药被评为第2级，表明其位列Zacks覆盖股票的前20%，具有优异的盈利预测修正特征 [10]

Teva Pharmaceutical Industries Ltd. (TEVA) closed the last trading session at $19.42, gaining 2.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $24.88 indicates a 28.1% upside potential.The average comprises eight short-term price targets ranging from a low of $20.00 to a high of $29.00, with a standard deviation of $2.53. While the lowest estimate indicates an increase of 3% fr ...